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SUMMARY
The genomic regulatory programs that underlie human organogenesis are poorly understood. 
Pancreas development, in particular, has pivotal implications for pancreatic regeneration, cancer, 
and diabetes. We have now characterized the regulatory landscape of embryonic multipotent 
progenitor cells that give rise to all pancreatic epithelial lineages. Using human embryonic 
pancreas and embryonic stem cell-derived progenitors we identify stage-specific transcripts and 
associated enhancers, many of which are co-occupied by transcription factors that are essential for 
pancreas development. We further show that TEAD1, a Hippo signaling effector, is an integral 
component of the transcription factor combinatorial code of pancreatic progenitor enhancers. 
TEAD and its coactivator YAP activate key pancreatic signaling mediators and transcription 
factors, and regulate the expansion of pancreatic progenitors. This work therefore uncovers a 
central role of TEAD and YAP as signal-responsive regulators of multipotent pancreatic 
progenitors, and provides a resource for the study of embryonic development of the human 
pancreas.
The human genome sequence contains instructions to generate a vast number of 
developmental programs. This is possible because each developmental cellular state uses a 
distinct set of regulatory regions. The specific genomic programs that underlie human 
organogenesis, however, are still largely unknown1,2. Knowledge of such programs could be 
exploited for regenerative therapies, or to decipher developmental defects underlying human 
disease.
The pancreas hosts some of the most debilitating and deadly diseases, including pancreatic 
ductal adenocarcinoma and diabetes mellitus. Classic mouse knockout models and human 
genetics have uncovered multiple transcription factors (TFs) that regulate embryonic 
formation of the pancreas3,4. For example, GATA65-7, PDX18,9, HNF1B10, ONECUT111, 
FOXA1/FOXA212, SOX913,14 and PTF1A15, are essential for the specification of pancreatic 
multipotent progenitor cells (MPCs) that arise from the embryonic gut endoderm, or for 
their subsequent outgrowth and branching morphogenesis. However, little is known 
concerning how these pancreatic TFs are deployed as regulatory networks, or which 
genomic sequences are required to activate pancreatic developmental programs.
One obvious limitation to study the genomic regulation of human organogenesis lies in the 
restricted access and the difficulties of manipulating human embryonic tissue. Theoretically, 
this can be circumvented by using human embryonic stem cells (hESCs) to derive cellular 
populations that express organ-specific progenitor markers, although it is unclear if such 
cells can truly recapitulate broad genomic regulatory programs of genuine progenitors.
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In the current study, we dissected pancreatic buds from human embryos and used hESCs to 
create stage-matched pancreatic progenitor cells. We processed both cellular sources in 
parallel and validated in vitro MPCs as a model to study gene regulation in early pancreas 
development. We created an atlas of active transcripts and enhancers in human pancreatic 
MPCs, and mapped the genomic binding sites of key pancreatic progenitor TFs. Using this 
resource, we show that TEA domain (TEAD) factors are integral components of the 
combination of TFs that activates stage- and lineage-specific pancreatic MPC enhancers.
RESULTS
Regulatory landscape of in vivo and in vitro MPCs
To study the genomic regulatory programs of the nascent embryonic pancreas, we dissected 
pancreatic buds from Carnegie Stage 16-18 human embryos. At this stage, the pancreas has 
a simple epithelial structure formed by cells expressing markers of pancreatic MPCs 
(including PDX1, HNF1B, FOXA2, NKX6.1 and SOX9), without obvious signs of 
endocrine or acinar differentiation, and is surrounded by mesenchymal cells (Supplementary 
Fig. 1a)16. For simplicity, we refer to this pancreatic MPC-enriched tissue as in vivo MPCs. 
Because human embryonic tissue is extremely limited and less amenable to perturbation 
studies, in parallel we used hESCs for in vitro differentiation of cells that express the same 
constellation of markers as in vivo MPCs (Supplementary Fig. 1a)17. We refer to these cells 
as in vitro MPCs. We performed RNA-seq and ChIP-seq analysis of in vivo and in vitro 
MPCs to profile polyadenylated transcripts, genomic sites bound by FOXA2 (a 
developmental TF that is specific to epithelial cells within the pancreas), and genomic 
regions enriched in the enhancer mark H3K4me1 (Fig. 1a, Supplementary Tables 1,2).
Earlier studies have shown that hESCs-derived pancreatic progenitors express appropriate 
markers17-20. However, the extent to which they provide a suitable model to study global 
genome regulation of genuine pancreatic MPCs has not been tested. Several observations 
validated our artificial progenitors for this purpose, namely: (a) in vitro MPCs recapitulated 
expression of known pancreatic MPC TFs (Fig. 1b, Supplementary Fig. 1b), (b) in vitro and 
in vivo MPCs showed a high correlation of transcript levels (Spearman's ρ=0.5876, 
P<2.2×10−16, Supplementary Fig. 1c) and of transcript enrichment relative to other human 
tissues (Spearman's ρ=0.5881, P<2.2×10−16, Fig. 1b,c, Supplementary Fig. 1d), and (c) the 
transcripts that are selectively enriched in either in vitro or in vivo MPCs relative to 22 non-
pancreatic tissues (Fig. 1b) share common functional annotations, including pancreas 
development, chordate embryonic development, and WNT signaling (Fig. 1d, 
Supplementary Table 3). The enrichment of WNT signaling genes included numerous non-
canonical WNT regulators, including FZD2, SFRP5, CELSR2, and VANGL2 (Fig. 1d, 
Supplementary Table 3), whose orthologs have also been listed as selectively expressed in 
mouse embryonic pancreatic buds (Supplementary Table 4)21,22, suggesting an evolutionary 
conserved signaling mechanism operating in early pancreas development. This indicates that 
despite the artificial origin of in vitro MPCs, and the presence of non-epithelial cell types in 
dissected embryonic pancreas, there are meaningful similarities in their transcriptomes. 
Integration of these datasets allowed us to define a core set of 500 genes that showed 
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enriched expression in both sources of pancreatic MPCs (Supplementary Table 5), providing 
a resource to study genes important for early human embryonic pancreas development.
We next compared FOXA2 binding sites in the in vivo and in vitro pancreatic MPCs with 
other tissues where this TF is expressed (embryonic liver, adult liver, and adult pancreatic 
islets)(Fig. 1e,f). FOXA2 largely bound to the same genomic regions in both sources of 
MPCs, yet bound to different genomic sites in other tissues, despite that a similar sequence 
motif was recognized in all cases (Fig. 1f, Supplementary Fig. 1e). Furthermore, in vivo and 
in vitro MPCs shared cell-specific H3K4me1 enrichment at in vivo FOXA2-bound sites 
(Fig. 1g, Supplementary Fig. 1f). Finally, genes with two or more nearby H3K4me1-
enriched FOXA2-bound regions in the in vivo MPCs showed enriched mRNA expression in 
both in vivo and in vitro MPCs relative to 23 control tissues (Fig. 1h). Thus, in vitro and in 
vivo MPCs showed common FOXA2 and H3K4me1 occupancy patterns near pancreatic 
MPC-enriched genes. Taken together, our analyses suggest that artificial pancreatic MPCs 
recapitulate significant transcriptional and epigenomic features of genuine embryonic 
MPCs, and can thus be exploited as a tool to study genome regulation of human pancreas 
development.
An atlas of human pancreatic MPC enhancers
To map active cis-regulatory elements in human pancreatic MPCs, we employed in vitro 
MPCs to profile H3K27ac, which marks active transcriptional enhancers23,24. We then 
selected all genomic regions that showed H3K27ac and H3K4me1 enrichment in chromatin 
from in vitro MPCs, and that were also enriched in H3K4me1 in human Carnegie Stage 
16-18 pancreas (in vivo MPCs). After exclusion of annotated promoters, this disclosed 9,669 
regions that carried an active enhancer chromatin signature in pancreatic MPCs (Fig. 2a, 
Supplementary Fig. 2a,b, Supplementary Table 6).
The cis-regulatory map included known pancreatic MPC enhancers (Fig. 2a). As expected, 
predicted MPC enhancer sequences showed strong evolutionary conservation (Fig. 2b), they 
were preferentially located near genes with increased expression in Carnegie Stage 16-18 
pancreas (Fig. 2c), and they were often associated with core MPC-specific genes 
(Hypergeometric test, P<10−15). In keeping with the cellular and temporal specificity of 
enhancers, 35% of pancreatic MPC enhancers showed no overlap with active enhancers 
from at least six of seven non-pancreatic tissues, and were thus defined as MPC-selective 
enhancers (Fig. 2d, Supplementary Fig. 2c, Supplementary Tables 7,8). Notably, 47% 
showed no overlap with enhancers from adult human islets25 (Fig. 2d). As expected from 
this cell-specific and stage-specific profile, genes near MPC-selective enhancers have 
functions relevant for pancreas development (Supplementary Fig. 2d, Supplementary Table 
9). This analysis therefore uncovered a large collection of candidate active enhancers of the 
nascent human embryonic pancreas.
A combinatorial code for pancreatic MPC enhancers
To understand the regulatory sequence code that drives early human pancreas development, 
we examined this collection of MPC enhancers and found that the most enriched sequence 
motifs match binding sites of known pancreatic regulators, including FOXA, HNF1, SOX, 
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PDX1, GATA, and ONECUT (Fig. 3a, Supplementary Fig. 3a, Supplementary Tables 
10,11). The single most enriched recognition motif, however, matched that of TEA domain 
(TEAD) TFs, which have not been previously implicated in pancreas development (Fig. 3a). 
TEAD motifs were similarly enriched in regions bound by FOXA2 in Carnegie Stage 16-18 
pancreas as well as in vitro MPCs, but not in regions bound by FOXA2 in adult pancreatic 
islets or liver (Fig. 3b, Supplementary Fig. 3b). Because TFs are thought to function in a 
combinatorial manner, we identified combinations of multiple motifs that were most 
enriched at pancreatic MPC enhancers relative to non-pancreatic enhancers (Fig. 3c, 
Supplementary Table 12). This showed that the most enriched combinations contained 
TEAD motifs adjacent to known pancreatic TF recognition sequences (Fig. 3c). These 
results therefore revealed that pancreatic MPC enhancers contain combinations of motifs 
that match known as well as previously unrecognized pancreatic regulatory TFs.
TEAD1 is a core component of pancreatic progenitor cis-regulatory modules
Mouse and human genetics have revealed numerous TFs that are essential for the 
specification, growth and morphogenesis of pancreatic MPCs3,26, yet very little is known 
about how such factors promote these processes. The availability of large numbers of in 
vitro MPCs allowed us to perform ChIP-seq analysis to profile the occupancy sites of 
several TFs that are essential for early pancreas development, namely HNF1B10, 
ONECUT111, PDX18,9 and GATA65-7, in addition to FOXA212 (Supplementary Table 2). 
Based on our computational predictions we also profiled TEAD1, a TEAD homolog that is 
highly expressed in MPCs from human embryonic pancreas (Supplementary Fig. 4a), 
defining binding sites for a total of six TFs in human MPCs (Fig. 4a).
All six TFs preferentially bound to known cognate recognition sequences that were widely 
distributed throughout the genome (Supplementary Fig. 4b), although there was marked 
preference for binding to MPC enhancers and annotated promoters (Fig. 4a,b, 
Supplementary Fig. 4c-d). Furthermore, the six TFs very frequently co-occupied the same 
regions, predominantly at MPC enhancers (Fig. 4a,b, Supplementary Fig. 4c-e). For 
example, enhancers bound by PDX1 and GATA6, the TFs with the lowest total number of 
binding sites, showed co-binding by at least one of the other five TFs in 94.5% and 95.3% of 
instances, respectively (Supplementary Fig. 4e). Remarkably, TEAD1 showed a similar co-
binding pattern as the five known pancreatic regulators analyzed in this study (Fig. 4c, 
Supplementary Fig. 4d,e). Consistently, strong TEAD1 occupancy was not only observed at 
known targets from other cell types, such as CTGF or CYR6127 (Supplementary Fig. 4f, 
Supplementary Table 13), but also in 27% of all pancreatic MPC enhancers. Furthermore, 
45% of enhancer-associated genes had at least one TEAD1-bound enhancer (Fig. 4d, 
Supplementary Table 14). In support, we confirmed TEAD1 binding to 10/12 enhancers in 
Carnegie Stage 16-18 embryonic pancreas (Fig. 4e, Supplementary Table 15), and observed 
that TEAD1 binding was enriched in enhancers bound by FOXA2 in vivo (Fig. 4f). 
Altogether, computational and ChIP-seq analysis indicate that known pancreatic regulatory 
TFs show widespread co-binding at MPC enhancers, and that TEAD1 is an unexpected 
component of this combinatorial TF code.
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Given the high degree of TF co-occupancy in MPC enhancers, we defined 2,945 regions 
within enhancers that are bound by 2 or more TFs, and coined these cis-regulatory modules 
(CRMs)(Fig. 4a, Supplementary Fig. 4c). CRMs provided greater spatial resolution of cis-
regulatory sequences than H3K27ac/H3K4me1-enriched regions alone, which often appear 
to merge several adjacent evolutionary conserved sequences bound by multiple TFs.
A large number of CRMs mapped near known pancreatic regulatory genes, including 
HNF1B, FGFR2, HHEX, FOXA2, NKX6-1, and SOX9 (Fig. 4a, Supplementary Fig. 4c, 
Supplementary Table 16). More generally, CRMs mapped near core MPC-enriched genes 
(P=3.32×10−12). Notably, spatial clusters of CRMs were associated to genes that were 
highly enriched in gene functions relevant for early pancreas development, including 
epithelial cell proliferation and WNT signaling (Fig. 4g, Supplementary Tables 17-19). 
Notably, non-canonical WNT regulatory genes were enriched near clusters of CRMs 
(P=1.18×10−9)(Supplementary Table 19), in agreement with our transcriptome analysis (Fig. 
1c, Supplementary Table 4) and transcriptome analysis of mouse pancreas development21,22.
Interestingly, CRMs bound by any of the six TFs were associated to the same functional 
annotations (Fig. 4g). This included TEAD1-bound CRMs, despite that this TF is widely 
expressed across multiple tissues and developmental stages (Fig. 4g). TEAD1-bound CRMs 
thus mapped to known or plausible pancreatic regulatory genes including FGFR2, RBPJ, 
FZD5/7/8, FRZB, JAG1, CDC42EP1, MAP3K1, NKX6-1, HHEX, GATA4, GATA6, FOXA2, 
HES1, and SOX9 (Fig. 4a, Supplementary Fig. 4c, Supplementary Table 20). This is 
consistent with a broad combinatorial function of regulatory TFs in the establishment of the 
MPC-specific transcriptional program.
To functionally validate these human embryonic pancreas CRMs, 32 sequences were 
transfected into in vitro MPCs, and 20 (62.5%) yielded significant enhancer activity (Mann-
Whitney for CRMs vs. control regions, P=0.0144)(Fig. 5a, Supplementary Fig. 5a). To 
directly test the function of TEAD1 binding to CRMs, we mutated TEAD recognition 
sequences in three CRMs that were bound by TEAD and other pancreatic TFs, which 
disrupted enhancer activity in all cases (Fig. 5b).
We selected 10 CRMs for validation using zebrafish transgenesis, and in 8 cases we 
demonstrated enhancer activity in Pdx1+/Nkx6.1+ pancreatic endoderm MPCs (Fig. 5c-e, 
Supplementary Fig. 5b, Supplementary Table 21). Amongst these, we examined a CRM in 
the locus encoding SOX9, an essential regulator of the self-renewal of mouse pancreatic 
MPCs that is mutated in humans with pancreas hypoplasia13,14 (Fig. 5c,d). This CRM 
showed pancreas-specific enhancer activity in zebrafish transgenics, whilst mutation of the 
TEAD recognition sequence abolished enhancer activity, providing further confirmation that 
TEAD1 binding is required for the in vivo function of pancreatic MPC enhancers (Fig. 5c).
Taken together, this analysis provided a rich source of cis-regulatory elements in human 
embryonic pancreatic progenitors. It also revealed widespread co-occupancy of pancreatic 
developmental TFs at MPC enhancers, and uncovered TEAD as a hitherto unrecognized 
core component of this combination of TFs.
Cebola et al. Page 6
Nat Cell Biol. Author manuscript; available in PMC 2015 November 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
TEAD and YAP regulate a pancreas developmental program
We next examined TEAD-dependent gene regulation during pancreas development. TEAD 
proteins interact with the active nuclear form of the coactivator Yes-associated protein 
(YAP). YAP is negatively regulated by Hippo signaling, which triggers YAP 
phosphorylation and nuclear exclusion27. We examined nuclear localization of YAP 
throughout differentiation, and found that YAP was highly expressed in the nucleus of 
hESCs, and subsequently showed low yet detectable immunoreactivity throughout 
intermediary stages of the in vitro pancreatic differentiation protocol (Supplementary Fig. 
6a), as well as in the nucleus of dorsal foregut epithelial cells of Carnegie Stage 10 human 
embryos (Supplementary Fig. 6b). Strong YAP expression was subsequently observed in the 
nucleus of in vitro-derived pancreatic MPCs, as well as human and mouse in vivo pancreatic 
MPCs (Carnegie Stage 18 and E10.5-E14.5 embryos, respectively)(Fig. 6a, Supplementary 
Fig. 6c-f,h), in keeping with recent descriptions in mice28. By contrast, YAP 
immunoreactivity was undetectable or delocalized to the cytoplasm in NGN3+ endocrine-
committed progenitors, differentiated acinar cells or endocrine cells (Fig. 6b,c, 
Supplementary Fig. 6c-g,i), although nuclear expression was maintained in ductal cells 
(Supplementary Fig. 6f). Furthermore, in pancreatic MPCs YAP bound to most tested 
TEAD1-bound regions (Fig. 6e), similar to what has been observed in other cell types that 
exhibit nuclear YAP expression27. Thus, during embryonic pancreas development the 
coactivator YAP shows stage-specific nuclear localization in MPCs. This suggests a YAP-
dependent function of TEAD1 during early pancreas development that is confined to MPCs, 
and is then inactivated upon differentiation of pancreatic lineages.
To study YAP-dependent TEAD function in pancreatic MPCs, we first used Verteporfin 
(VP), a chemical compound that disrupts the TEAD-YAP complex29. VP treatment of 
human in vitro MPCs and pancreatic bud explants dissected from E11.5 mouse embryos and 
grown ex-vivo caused decreased expression of a subset of genes associated with TEAD1-
bound enhancers, including genes that are established critical regulators of progenitor cell 
growth in the embryonic pancreas, such as FGFR230 and SOX914,31, as well as mediators of 
growth regulatory pathways, such as NOTCH1 and the known Hippo target CCND1 
(encoding Cyclin D1)(Fig. 7a,b, Supplementary Fig. 4f). Consistently, exposure of mouse 
explants to VP during 24 h significantly reduced epithelial cell proliferation by 39% 
(P=0.006)(Fig. 7c), and limited the growth of pancreatic buds to 27% of control organs after 
3 days in culture (P=0.038)(Fig. 7d). These results suggest that the TEAD-YAP complex 
has direct effects on several known regulators of pancreatic progenitors, and is required for 
the proliferation and growth of early embryonic pancreas epithelium.
To further test the in vivo function of YAP and TEAD in pancreas development, we 
performed genetic perturbations in zebrafish. In keeping with our chemical inhibition 
studies, morpholino inhibition of yap1 caused a reduction in the pancreas size at 48 hpf, with 
hypoplasia in 65% of embryos (n=46)(Supplementary Fig. 7a), and a marked reduction of 
sox9b-expressing pancreatic MPCs (Fig. 7f,g). This effect was partially rescued by co-
injection with yap1 mRNA, confirming the morpholino specificity (Supplementary Fig. 7a). 
In agreement, zebrafish embryos expressing a TEAD protein fused to the transcriptional 
repressor domain of Engrailed32, phenocopied the morpholino inhibition of yap1 (Fig. 7g, 
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Supplementary Fig. 7a). In summary, inhibition of Yap1 and Tea domain proteins in 
zebrafish suppressed pancreatic sox9b expression and cell growth, in agreement with our 
mouse and human in vitro studies. Given that TEAD directly regulates a SOX9 enhancer 
(Fig. 5c), and that SOX9 regulates mouse and human pancreatic MPC growth13,14,31, we 
hypothesize that the effects of TEAD and YAP on pancreatic progenitors are partially 
mediated through SOX9. Taken together, genetic and chemical inhibitor experiments support 
a model whereby YAP coactivation of TEAD1-bound MPC enhancers regulate a genomic 
regulatory program that is required for the expression of stage-specific genes and for the 
outgrowth of pancreatic progenitors.
DISCUSSION
We have created and validated a map of active enhancers in human embryonic pancreatic 
progenitors. This effort expands the current list of known active enhancers in the embryonic 
pancreas from a handful of examples to thousands of stage-specific cis-regulatory elements. 
This included clustered enhancers, which were linked to a core cell-specific transcriptional 
program, in analogy to earlier studies in diverse cellular lineages25,33. Our studies also show 
that pancreatic embryonic progenitor cells derived from hESCs mimic salient transcriptional 
and epigenomic features of pancreatic progenitors from human embryos, illustrating the 
power of pluripotent stem cell biology to dissect regulatory mechanisms underlying human 
embryogenesis.
This atlas of pancreatic MPC enhancers should facilitate the discovery of non-coding 
mutations that cause human diseases linked to abnormal pancreas development. In support 
for this claim, H3K4me1, PDX1 and FOXA2 binding data from in vitro MPCs enabled the 
identification of recessive mutations that map to a previously unannotated enhancer of 
PTF1A and cause isolated pancreas agenesis34. Sequence variation in MPC enhancers could 
hypothetically increase the susceptibility to type 2 diabetes mellitus by impacting pancreas 
development and thereby affecting the pancreatic beta cell mass. Finally, germ-line or 
somatic variants in MPC enhancers could also influence the development of pancreatic 
adenocarcinoma, which has been associated with dedifferentiation of adult exocrine 
cells35,36 and to YAP activation37,38.
Our study identifies binding sites of several TFs that are known to be essential for early 
pancreas development, and show that they co-occupy pancreatic MPC enhancers, consistent 
with a combinatorial TF code. Unexpectedly, our results revealed that TEA domain proteins 
– exemplified by TEAD1 – and the coactivator YAP are central components of this 
combinatorial code, activating key regulatory genes and promoting the outgrowth of 
pancreatic MPCs.
The TEAD-dependent transcriptional mechanism provides a means for signal-responsive 
dynamic regulation of MPC enhancers during pancreas development. The coactivator YAP 
is a component of the Hippo signaling cascade, which phosphorylates YAP, leading to its 
retention in the cytoplasm or to its degradation39. Our data shows that, as human pancreatic 
MPCs transition to endocrine and acinar lineages, YAP undergoes immediate nuclear 
exclusion and downregulation. Based on our chemical and genetic experiments, this 
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dynamic change is expected to lead to inhibition of MPC enhancers during pancreatic 
differentiation.
Two recent reports showed that pancreas-specific disruption of the upstream Hippo kinases 
Mst1/2 leads to increased proliferation of adult acinar pancreatic cells, which acquire a duct-
like morphology, exhibit increased nuclear localization of Yap and show ectopic expression 
of the TEAD target Sox928,40. These observations do not address whether Hippo signaling 
or TEAD are important for pancreatic progenitors, but they are consistent with failed 
suppression of a progenitor program in adult cells, and therefore support the predictions 
from our findings. Collectively, existing data suggests a model whereby TEAD proteins 
provide a regulatory switch that activates a stage-specific transcriptional program in 
pancreatic MPCs, and facilitates signal-responsive inactivation of this program during 
pancreatic cell differentiation (Fig. 8).
Further studies should explore this regulatory mechanism in human disease. The reactivation 
of the YAP/TEAD-dependent MPC enhancer program in adult acinar cells could 
conceivably activate a progenitor-like cellular program during early stages of pancreatic 
carcinogenesis36,41, and/or contribute to YAP-dependent cancer progression37,38. This same 
genetic program could potentially be exploited to control growth and differentiation during 
the generation of artificial pancreatic cells.
METHODS
Human samples
Human embryos were collected with informed consent with approval from the North West 
Regional Ethics Committee (08/H1010/28) following termination of pregnancy and staged 
immediately by stereomicroscopy according to the Carnegie classification48. The collection, 
use and storage of material followed guidelines from the UK Polkinghorne Committee, 
legislation of the Human Tissue Act 2004 and the Codes of Practice of the Human Tissue 
Authority, UK. The analysis of human embryonic tissue was also approved by the Comitè 
Ètic d’Investigació Clínica del Centre de Medicina Regenerativa de Barcelona and 
Departament de Salut, Generalitat de Catalunya. Human embryonic pancreas and liver were 
dissected at Carnegie Stage (CS) 16-18, which correlates to ~37-45 days post-conception. 
These stages were the earliest at which pancreatic epithelial cells could be efficiently 
dissected away from surrounding mesenchyme with minimal contamination. After isolation 
tissues were rinsed with PBS, incubated 10 min in 1% formaldehyde, 5 min in 125 mM 
Glycine, rinsed in PBS containing protease inhibitor cocktail (Roche) at 4°C, and snap-
frozen and stored at −80°C. RNA was extracted using Trizol and DNase.
Human ESCs (H9, WiCell) were imported under guidelines from UK Stem Cell Bank 
Steering Committee (SCSC10-44). Differentiation of pancreatic MPCs has been 
described17. Briefly, definitive endoderm (DE) was induced by growing hESCs in CDM-
PVA + Activin-A(100 ng/mL), BMP4(10 ng/mL), bFGF(20 ng/mL) and LY(10 μM)
(AFBLy). The CDM-PVA AFBLy cocktail was replenished daily, and daily media changes 
were made until differentiation day 10. After the DE stage (days 1-3), cells were cultured in 
Advanced DMEM (Invitrogen) with SB-431542(10 μM; Tocris), FGF10(50 ng/ml; Autogen 
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Bioclear), all-trans retinoic acid (RA, 2 μM; Sigma) and Noggin (150 ng/ml; R&D Systems) 
during days 4-6. For days 7-9, cells were supplemented with human FGF10 (50 ng/ml; 
Autogen Bioclear), all-trans retinoic acid (RA, 2 uM; Sigma), KAAD-cyclopamine (0.25 
μM; Toronto Research Chemicals) and Noggin (150 ng/ml; R&D Systems). On days 10-12, 
cells were cultured in human FGF10 (50 ng/ml; Autogen Bioclear), all-trans retinoic acid 
(RA, 2 uM; Sigma), and KAAD-cyclopamine (0.25 μM; Toronto Research Chemicals).
For RNA-seq and ChIP-seq, cells from 3 independent differentiation experiments were 
pooled. For ChIP cells were fixed as described above, snap-frozen and kept at −80°C. Total 
RNAs were extracted from hESCs or differentiated progenitors using the RNeasy Mini Kit 
(Qiagen) and treated with RNase-Free DNase (Qiagen).
Immunolocalization
Immunolocalization was performed as described16,17,49,50. Antibodies are listed in 
Supplementary Table 23.
Pancreatic explants from E12.5 C57BL/6 mouse embryos and whole mount stainings were 
performed as described51 with modifications. Briefly, pancreas were fixed 20 min in 4% 
paraformaldehyde, blocked in 0.5% Triton X-100/10% FBS/PBS overnight at 4°C, 
incubated 24 hours with primary antibody at 4°C, then overnight with secondary antibody at 
4°C and finally DAPI staining. EdU staining was performed using Click-iT EdU Alexa 
Fluor® 488 Imaging Kit (Invitrogen). All images presented show representative results 
obtained from at least 3 independent experiments.
Chromatin Immunoprecipitation (ChIP)
Either 7 human CS16-18 pancreatic buds, 4 CS16-18 liver buds (as described above), or ~10 
million cells from a pool of 3 pancreatic progenitor in vitro differentiation experiments, 
were pooled in 1 mL of lysis buffer containing protease inhibitor cocktail (Roche) and 
sonicated 10-15 cycles essentially as described25,52. We verified that a substantial portion of 
chromatin fragments were in the 200-600 bp range by gel electrophoresis.
ChIP was performed with 50-300 μL of sonicated chromatin as described25,53,54, with minor 
modifications. Briefly, sonicated chromatin was diluted with ChIP dilution buffer (0.75% 
Triton X-100, 140 mM NaCl, 0.1% sodium deoxycholate, 50 mM Hepes at pH8.0, 1 mM 
EDTA, 1X protease inhibitor cocktail) to achieve a final SDS concentration of 0.2%, pre-
cleared with A/G sepharose beads (GE Healthcare) for 1 hour, incubated overnight at 4°C 
with 1-1.5μg antibodies (Supplementary Table 23), rotated 2 hours at 4°C with A/G 
sepharose beads, and then sequentially washed and processed25,53,54.
RNA-seq
All samples had RIN >9. RNA-seq was generated from DNase-treated PolyA+ RNA from a 
CS17 pancreatic bud or from a pool of 3 in vitro pancreatic MPC differentiation 
experiments, sequencing 90-nucleotide reads with an Illumina HiSeq 2000 instrument. 
RNA-seq datasets from 23 tissues and their sources are listed in Supplementary Table 1. 
Reads were aligned to the NCBI36/hg18 genome using TopHat-v1.2.055 with default 
Cebola et al. Page 10
Nat Cell Biol. Author manuscript; available in PMC 2015 November 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
parameters, allowing only 1 mismatch per read. For comparison of RNA levels, we 
processed and calculated fragments per kilobase of exon per million fragments mapped 
(FPKM) values for each transcript as described56. For a global comparison of gene 
expression profiles (Supplementary Fig. 1c), we analyzed 44,699 UCSC gene variants 
expressed at >5 FPKM in at least one sample. Expression values were median-centered and 
scaled by the root mean square. Spearman correlation values were calculated for each pair.
RNA enrichment analysis
Tissue-selectivity of each transcript was assessed by computing the FPKM coefficient of 
variance (CV) in the 25 samples described in Supplementary Table 1. To obtain the 
enrichment of each transcript in each tissue, we calculated Z-scores as the difference 
between the log2-transformed expression level in the specific tissue and the mean of all 
tissues, divided by the standard deviation. For detection of MPC-specific transcripts Z-score 
measurements were calculated without data from islets and either in vitro or in vivo MPCs. 
We defined tissue-specific genes as those with CV ≥1, expression ≥0.3 FPKM and Z-score 
≥1 in any tissue.
Core MPC-specific genes were defined as UCSC annotated genes that were tissue-selective 
(CV ≥1) and enriched in in vitro MPCs (Z-score ≥1). We then sorted by in vivo MPC 
enrichment Z-score, and selected the top 500 (Supplementary Table 5).
Functional annotations
Transcript functional annotation was performed with DAVID57, using Gene Ontology (GO) 
biological process (FAT), Pathways (KEGG, Panther) and annotation clustering. In Fig. 1c, 
we sorted terms by P value and show the most significant term of each cluster. Annotations 
are provided in Supplementary Table 3.
Genes associated with enhancers and CRMs were analyzed with GREAT-v2.0.245 applying 
default settings (basal plus extension; significant by both binomial and hypergeometric 
tests), and annotated with GO Biological Process plus all pathway annotations. Raw 
binomial P value and binomial fold enrichment were used to present enrichments. 
Supplementary Tables 9, 17 and 19 list annotations associated with MPC-selective 
enhancers, CRMs, and CRM clusters, respectively. GO Biological Process terms were 
further processed with REVIGO46 (0.9 allowed similarity; term size database–whole 
UniProt; semantic similarity measure–normalized Resnik; cluster definition default 
parameters) taking the most significant term in each GO cluster.
ChIP-seq
Chromatin from replicate pools of in vitro MPCs was used for FOXA2 and H3K4me1 ChIP-
seq experiments. Single libraries were prepared from chromatin pools for all other ChIP-seq 
experiments, except for FOXA2 in vivo MPC, in which libraries from 2 experiments were 
sequenced and reads were pooled for alignment. All libraries were prepared with 5-10 ng 
DNA and sequenced with Illumina HiSeq2000 platform were aligned to NCBI36/hg18 using 
Bowtie-v0.12.7 (Supplementary Table 2), allowing unique alignment with ≤1 mismatch. 
Post-alignment processing included in silico extension, signal normalization based on the 
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number of million mapped reads, extension to MACS fragment size estimation (v1.4.0beta), 
and retention of only unique reads. For signal normalization, the number of reads mapping 
to each base in the genome was counted with genomeCoverageBed (BedTools-v2.17.0). TF 
enrichment sites were detected with MACS-v1.4.0beta using default parameters and 
P<10−10. Background model was defined with input DNA sequence. SICER-v1.03 was used 
to call H3K4me1-enriched islands with window size =100 bp, gap size=800 bp and fragment 
size estimated by MACS-v1.4.0beta. Enriched islands were called at FDR<10−3. For 
H3K27ac-enriched regions gap size was 200 bp. For replicate samples we retained 
overlapping peaks/islands in replicates. To compute FOXA2 and H3K4me1 signal 
correlations between duplicates we divided the genome in 1 or 5 Kb bins, respectively, then 
counted unique reads in each bin and quantile-normalized results. Bins with values <5th 
percentile in both samples were excluded from the analysis. Pearson correlation values were 
0.8-0.9 in all biological replicates (Supplementary Fig. 1g). Public datasets were processed 
identically (listed in Supplementary Table 2).
TF and H3K4me1 aggregation plots
To compute aggregation plots (Figure 1f) we first selected “tissue-specific regulatory 
regions”, defined by the intersections of H3K4me1 islands with TF “peaks” in the same 
tissue. The resulting number of regions were as follows: FOXA2 in in vivo MPCs (2,307), 
SOX2 in hESCs (5,749), MEIS1 in CD133+ cells (2,210), DNase I peaks containing ETS1 
motifs in mammary epithelial cells (14,100) and DNase I peaks containing MEF2A motifs 
in myotube cells (13,614). Next, regions spanning +/−3 Kb from the center of TF peaks 
were divided in 100 bp bins. The coverage signal was obtained using coverageBed 
(BedTools-v2.17.0). Data was quantile normalized after creating 100 bp bins in H3K4me1 
islands from each tissue.
Clustering
To compare ChIP-seq signals between tissues (Fig. 1e, Supplementary Fig. 1f), we 
generated 6 Kb windows centered on in vivo MPC FOXA2 peaks. Each window was divided 
in 100 bp and binned signal coverage was quantile normalized as described above. 
Hierarchical clustering was performed with Cluster358 with similarity metric set to 
Correlation (uncentered) and average linkage as clustering method. Heatmaps were 
visualized with Treeview59.
Definition of enhancers and CRMs
Enhancers were defined as H3K27ac islands in the in vitro MPCs that overlapped H3K4me1 
islands in both in vitro and in vivo MPCs. We discarded regions overlapping promoters (1 
Kb upstream and 2 Kb downstream of RefSeq TSS) or <50 bp. Enhancers in 8 control 
tissues were defined with analogous criteria based on H3K27ac and H3K4me1 islands 
(Supplementary Table 8).
To define CRMs we merged all in vitro MPC TF peaks that were <500 bp apart, and 
retained 2,945 regions bound by at least 2 different TFs that overlapped MPC enhancers by 
at least 1 bp.
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Clusters of CRMs were defined as described25, essentially as any group of ≥3 CRMs in 
which all adjacent CRMs were separated by less than the 25th-percentile of chromosome-
specific randomized distances.
Enhancer selectivity
MPC-selective enhancers were defined as those that showed no overlap with an enhancer 
from at least 6 out of 7 control tissues (hESCs, fetal muscle, fetal stomach, fetal thymus, 
mammary epithelial cells, myotubes and osteoblasts).
Conservation
Conservation was assessed in +/−3 Kb windows centered in enhancers, using average 
vertebrate PhastCons score from 17 species for 20 bp bins.
Motif analysis
De novo motif discovery was performed with HOMER44. For enhancers we searched for 
either short (length=6,8,10,12) or long (length=14,16,18,20) motifs as described 
previously25, retaining non-redundant matrices (Pearson correlation <0.65) with P<10−50. 
Motifs were annotated using HOMER44, TOMTOM60 and manual comparisons.
All possible combinations of 3 motifs from the 23 enriched motifs contained within 500 bp 
regions were computed in MPC enhancers vs. enhancers from 8 other tissues. We calculated 
eight MPC vs. control tissue fold-enrichment and P values (Chi-squared test), and then 
combined them in a unique P value for each motif combination with a Z-weighted 
method61. Supplementary Table 12 shows the top 50 most enriched combinations.
For TF peaks HOMER analysis was performed in 200 bp windows centered on peak 
summits and motif lengths were set to 8, 10 and 12 bp. Co-enriched motifs were manually 
curated to exclude redundant motifs. Known DNA binding motifs were associated to the de 
novo recovered matrix only if the HOMER score was >0.7.
Binding and co-binding enrichment analysis
To assess the enrichment of TF binding and co-binding in enhancers or promoters, the 
positions of the enhancers or promoters were randomized in all mappable hg18 coordinates 
using ShuffleBed (BEDTools-v2.17.0). Mappable regions were defined as those not 
annotated as genome gaps and with score of 1 in the CRG Mappability 50 bp track of the 
UCSC browser62. Binding enrichment was calculated over the median of 1,000 
permutations.
Co-bound regions were defined with intersectBed (BEDTools-v2.17.0) as regions bound by 
≥2 TFs. To calculate TF co-binding enrichment, we shuffled each TF individually in the 
mappable genome, and calculated the overlap with sites bound by the other TFs (median of 
1000 permutations generated by ShuffleBed, BEDTools-v2.17.0). Chi-squared test was 
applied to assess the enrichment of each combination of 2 TFs over expected co-binding. 
For comparison, we applied the same pipeline to define “co-binding” between MEIS1 in 
CD133+ cells and the six MPC TFs (Supplementary Table 2).
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Enhancer function assays in human cells
The pGL4.23[luc2/minP] vector (Promega) was modified by inserting a Gateway cassette 
upstream of the minimal promoter (pGL4.23-GW) for subsequent cloning of CRMs and 
control sequences. These 500-2000 bp sequences were amplified from human genomic 
DNA with Phusion High-Fidelity DNA Polymerase (New England Biolabs), cloned into 
pENTR/D-TOPO (Invitrogen), shuttled into pGL4.23-GW, and assessed by Sanger 
sequencing and restriction enzyme digestion. To mutate CRMs, we replaced a 3 bp sequence 
of the core of TEAD motifs, as this was previously shown to disrupt TEAD binding27, and 
confirmed by Sanger sequencing. Oligonucleotides are available in Supplementary Table 15.
At day 10 of the differentiation protocol, cells were transfected in 24-well plates with 
pGL4.23-CRM plasmids (400 ng) and Renilla normalizer plasmid (4 ng) using 
Lipofectamine 2000 (Invitrogen). Luciferase was measured at day 13 with Dual-Luciferase 
Reporter Assay System (Promega). The results shown represent the average and SEM of 3 
(HMGA2, GLIS3 and MAP3K10) or 4 (all other CRMs and all negative controls) 
independent transfections per construct. Eight of 32 plasmids in Figure 5a and 
Supplementary Figure 5a, and 6 of the 9 CRMs in Figure 5b were retested in independent 
experiments that yielded comparable results. Statistical significance was assessed with two-
tailed Student’s t test using all experiments (see Supplementary Table 22).
Pancreatic explant experiments
Mouse experiments were approved by the Comitè Étic d’Experimentació Animal 
(University of Barcelona) in accordance with national and European regulations. No 
statistical method was used to predetermine sample size. The experiments were not 
randomized. The Investigators were not blinded to allocation during experiments and 
outcome assessment. Pancreatic explants were carried out as described63 with minor 
modifications. Dorsal pancreatic buds from E11.5 CD-1 mouse embryos were cultured in 
RPMI medium with 10% FBS for 16 hours (day 1) prior to Verteporfin (VP) 0.1 μM 
(Atomax) or DMSO (control) treatment 24 hours in RPMI 3% FBS. After 24 hours (day 2), 
drug was washed out and buds were cultured 1 day in RPMI 10% FBS (day 3).
For quantitation of explant growth we used Sox9-EGFP transgenic embryos, which enabled 
visualization of pancreatic epithelial progenitors. We used ImageJ 1.46a to measure the area 
of EGFP-expressing cells on days 1 and 3. We performed 3 independent experiments, and 
examined 2-3 pancreas per condition in each experiment. We expressed areas as percentage 
of the baseline in the same explant, and used Mann-Whitney test to determine significance. 
Data failed to show normal distribution with Kolmogorov-Smirnov test.
To study epithelial cell proliferation, explants were exposed to EdU (1 μM) after VP 
treatment for 30 min and analyzed 24 hours later. We examined 2-4 pancreas per condition 
in each of 3 independent experiments. Mann-Whitney test was used for statistical 
significance.
We obtained RNA from pools of ≥3 pancreatic buds using the RNeasy Mini Kit (QIAGEN), 
and collected 3 separate pools from independent experiments. qRT-PCR was performed 
using a 7300 Real Time PCR System (Applied Biosystems) and Power SYBR Green PCR 
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master mix (Applied Biosystems). Each sample pool was amplified in duplicate using 
Gapdh for normalization. Oligonucleotides are shown in Supplementary Table 15. Statistical 
significance was assessed with two-tailed Student’s t test.
VP experiments in human progenitors
In vitro MPCs were subjected to VP (10 μM) or DMSO treatment for 16 hours in duplicate 
on day 12 of the differentiation protocol. The drug was washed out with PBS and RNA was 
extracted with RNeasy Mini Kit, Qiagen. Reverse transcription was carried out with 0.5 μg 
RNA using Superscript II (Invitrogen) and qPCR was performed using SensiMiX 
(Quantace). Oligonucleotide sequences are listed in Supplementary Table 15 and in 
reference17. qPCR reactions were normalized to PBGD and analyzed by two-tailed t test.
Zebrafish experiments
Zebrafish embryos from the same cross were randomly selected for the control, morphant 
(Mo-yap1), dominant negative (TEAD-EnR) and rescue (Mo-yap1+yap1 mRNA) 
conditions. Five nl of 2 mM morpholino targeting a splice junction of yap1 (yap1-Mo, 5′- 
AGCAACATTAACAACTCACTTTAGG -3′; previously reported64) were injected in yolk 
of 1- to 2-cell stage zebrafish embryos. Morpholino activity was confirmed by qRT-PCR 
(oligonucleotides 5′-TGCCAGACTCATTCTTCACG-3′, 5′-
TGGGAACCTTGCTTTACTGG-3′). For rescue experiments, yap1 mRNA (50 pg) was co-
injected with the Morpholino. The mRNA of mouse Tead2 fused with engrailed repressor 
domain (TEAD2-EnR) was synthesized using an existing vector57, and 200 pg was injected 
in the yolk of 1- to 2-cell stage zebrafish embryos. Embryos were fixed overnight at 4°C in 
4% paraformaldehyde in PBS. In situ hybridization for Sox9b65 and insulin66 was 
performed as described67 and revealed with NBT/BCIP substrate in 46-71 embryos per 
condition. After in situ hybridization, immunolocalization was performed for some embryos 
using antibodies listed in Supplementary Table 23. The number of Pdx1+/Sox9b+ pancreatic 
progenitors was counted in each embryo using confocal microscopy, and differences 
between groups were analyzed by two-tailed Student’s t test.
For transgenic analysis of CRMs wild type and mutant, zebrafish embryos from the same 
cross were randomly selected. DNA fragments were recombined to an enhancer test vector 
that is sequentially composed of: a Gateway cassette for insertion of CRMs, a gata2 minimal 
promoter, an enhanced GFP reporter gene, and a strong midbrain enhancer (z48) that works 
as an internal control for transgenesis. All these elements were previously reported68 and 
were assembled in a tol2 transposon69. Transgenesis was performed as described68 and 
embryos were grown to 24 and 48 hours post fertilization (hpf) at 28°C. GFP was 
documented using an epifluorescence stereomicroscope. Embryos positive for transposon 
integration were immunostained for simultaneous detection of Nkx6.1 plus either Pdx1 or 
insulin expression to identify pancreatic progenitors by confocal microscopy. Note that in 
zebrafish Nkx6.1 is expressed in pancreatic MPCs but not in endocrine cells, unlike 
mammalian embryos47. For each construct we counted embryos with GFP expression in 
Nkx6.1+ pancreatic cells (Supplementary Table 21).
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No statistical method was used to predetermine sample size. The Investigators were not 
blinded to allocation during experiments and outcome assessment.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Reproducibility of experiments
Figure 5c shows representative data from one independent experiment with 110-140 
zebrafish embryos per condition.
Figure 5d and Supplementary Figure 5b show representative data from 3-4 independent 
experiments. Each independent experiment consisted of 50-120 injections. The exact 
number of zebrafish embryos analyzed for each CRM is shown in Supplementary Table 21.
Figure 6a-d, Figure 7c,d,f, Supplementary Figure 1a, Supplementary Figure 6a-i and 
Supplementary Figure 7b show representative data from 3 independent experiments.
Figure 7g shows representative data from one independent experiment with 9-12 zebrafish 
embryos per condition.
Supplementary Figure 4a shows representative data from 6 independent experiments. Three 
immunostainings were performed independently for two human embryos (CS18 and CS19).
Supplementary Figure 7a shows representative data from one independent experiment with 
46-71 zebrafish embryos per condition.
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Figure 1. 
Human in vitro MPCs recapitulate transcriptional and epigenomic features of in vivo MPCs. 
(a) Experimental set-up. Pancreas was dissected from human Carnegie stage 16-18 embryos 
(in vivo MPCs). In vitro MPCs were derived from hESCs. (b) In vitro and in vivo MPCs 
share tissue-selective genes. Tissue-selectivity of RNAs was determined by the coefficient 
of variation (CV) across 25 embryonic and adult tissues or cell types. Enrichment of RNAs 
in MPCs relative to non-pancreatic tissues was quantified as a Z-score. Red lines define 
genes that are both tissue-selective and enriched in MPCs (CV>1, Z>1). Most known 
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pancreatic regulatory TFs are in this quadrant in both sources of MPCs. Color scale depicts 
number of transcripts. (c) Z-scores of genes expressed in at least one source of MPCs were 
highly correlated for in vitro vs. in vivo MPCs (see also Supplementary Figure 1d for a 
comparison of unrelated tissues). Spearman's coefficient value is shown. Color scale depicts 
number of transcripts. (d) In vivo and in vitro MPC-enriched genes have common functional 
annotations. Shown are most significant terms for in vivo MPC-enriched genes, and their 
fold enrichment in both sources of MPCs. Representative genes from each category that are 
enriched in both MPCs are shown on the right. More extensive annotations are shown in 
Supplementary Table 3. (e) RNA, FOXA2 and H3K4me1 profiles of indicated samples in 
the GATA6 and MNX1 loci. (f) In vivo MPC FOXA2 occupancy is largely recapitulated by 
in vitro MPCs, but not by other tissues expressing FOXA2. Hierarchical clustering was 
performed on normalized FOXA2 ChIP-seq signal centered on all 5,760 in vivo MPC 
FOXA2 peaks. (g) In vitro MPCs recapitulate cell-specific H3K4me1 enrichment observed 
in chromatin from in vivo MPCs. Aggregation plots show H3K4me1 enrichment at 
occupancy sites of tissue-specific TFs. Mam.: Mammary Myo.: Myotubes. (h) Genes with 
≥3 regions enriched in FOXA2 and H3K4me1 at in vivo MPCs are preferentially expressed 
in both in vivo and in vitro MPCs. Boxes show RNA interquartile range (IQR) and notches 
indicate median 95% confidence intervals (n=327 genes). P values were calculated with 
Wilcoxon rank-sum test.
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Figure 2. 
A compendium of active enhancers in human pancreatic MPCs. (a) Predicted enhancers 
were defined by enrichment in H3K27ac and H3K4me1 (see schematic in Supplementary 
Fig. 2b). Shown are examples in the vicinity of PDX1, including a previously unannotated 
enhancer which we coin Area V, upstream of known enhancers (Areas I-IV)42,43, and 
several enhancers near PRICKLE2, a non-canonical WNT signaling component 
(Supplementary Table 4). (b) MPC enhancer sequences are evolutionary conserved (17 
species vertebrate PhastCons score). Conservation plots of random non-exonic sequences 
are shown as a light gray line. (c) Genes that are associated with 3 or more MPC enhancers 
show enriched expression in dissected in vivo MPCs relative to 23 other tissues. The boxes 
show interquartile range (IQR) of RNA levels, whiskers extend to 1.5 times the IQR or 
extreme values, and notches indicate 95% confidence intervals of the median. P value was 
calculated with Wilcoxon rank-sum test (n=2,093 genes). (d) Many MPC enhancers are 
tissue- and stage-selective. We defined enhancers of 8 control tissues using identical criteria 
as in MPCs (Supplementary Fig. 2c, Supplementary Table 8) and show the proportion of 
enhancers that are inactive in at least 6 out of 7 non-pancreatic tissues (left) or inactive in 
adult pancreatic islets (right).
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Figure 3. 
MPC enhancers are enriched in DNA binding motifs for TEAD and known pancreatic 
transcription factors. (a) TEAD recognition motifs were strongly enriched in a de novo motif 
search in MPC enhancers. Other enriched matrices match binding sites of known pancreatic 
regulators. See Supplementary Tables 10 and 11 for a complete list of motifs enriched in 
MPC and MPC-selective enhancers, respectively. (b) TEAD motifs are highly enriched at 
genomic regions bound by FOXA2 in both in vivo and in vitro MPCs, but not at regions 
bound by FOXA2 in islets or liver. Binomial distribution P values were obtained using 
HOMER44. NS: non-significant. (c) Combinations of recognition motifs for TEAD and 
other pancreatic regulators are specifically enriched in pancreatic MPC enhancers. We 
searched for combinations of 3 sequence motifs that were contained within 500 bp and were 
most enriched in pancreatic MPC enhancers relative to 8 other tissue enhancers. The top 50 
most enriched motif combinations are shown in Supplementary Table 12.
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Figure 4. 
TEAD1 is a core component of human pancreatic MPC cis-regulatory modules (CRMs). (a) 
ChIP-seq was used to locate binding sites of 6 TFs in MPCs, as illustrated in two loci 
encoding pancreatic TFs. CRMs were defined as enhancer regions with ≥2 overlapping TF-
bound sites. Examples are highlighted in yellow. (b) TFs preferentially occupy MPC 
enhancers, and this is most pronounced for regions bound by ≥2 TFs. Binding enrichment 
was calculated over 1,000 permutations of enhancer or promoter genomic positions in the 
mappable genome. For comparison we analyzed all other genomic regions after exclusion of 
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MPC enhancers or promoters. Red line indicates a fold enrichment of 1. (c) Pancreatic TFs 
co-occupy genomic regions, and TEAD1 shows a similar co-occupancy pattern as other 
known pancreatic TFs. Binding sites of MEIS1 in a non-pancreatic cell type were used as 
control. The heatmap depicts Chi-squared values for all pairwise comparisons of observed 
vs. expected co-binding. The latter was estimated by permuting each set of TF peaks 
independently 1,000 times. (d) Over 1/4 of MPC enhancers are bound by TEAD1, whereas 
45% of genes associated with MPC enhancers include at least one TEAD1-bound enhancer. 
(e) ChIP-qPCR with in vivo MPCs confirms TEAD1 binding at in vitro MPC TEAD1-bound 
regions (regions and associated genes in Supplementary Table 15). (f) TEAD1 binding is 
enriched in regions bound by FOXA2 in either in vitro or in vivo MPCs. We calculated 
TEAD1-FOXA2 co-binding over the median expected value after generating 1,000 
permutations of in vitro or in vivo FOXA2 peak positions. (g) CRMs underlie a pancreas 
developmental regulatory network. The 2,956 genes associated with CRMs were 
functionally annotated using GREAT45, and REVIGO46 was used to visualize annotation 
clusters. The most significant terms from each cluster are highlighted according to the P 
value color scale. Bar graphs show that GO terms are similarly enriched in CRMs bound by 
different TFs. *Several WNT pathway related-terms were enriched, although manual 
annotation in this category revealed that most gene were either non-canonical WNT 
signaling mediators or antagonists of canonical WNT signaling (full annotations in 
Supplementary Table 17).
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Figure 5. 
Functional validation of CRMs as transcriptional enhancers. (a) Thirty two CRMs were 
cloned into the pGL4.23 vector and tested in reporter assays, where 20 (62.5%) yielded 
significant activation of a minimal promoter driving luciferase in human pancreatic MPCs. 
Lines represent median with IQR. Two-tailed Mann-Whitney test P value is shown (n=4 
replicate wells). (See also Supplementary Fig. 5a). (b) TEAD binding sites are essential for 
MPC enhancer activity. Mutation of one or more canonical TEAD binding sites in three 
CRMs abolished their activity in luciferase reporter assays in in vitro MPCs. Locations of 
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the FGFR2 and MAP3K1 CRMs are highlighted in Figure 4a and Supplementary Figure 4c, 
respectively. Two-tailed t-test P values are listed in Supplementary Table 22 (n=3-4 
transfections per construct, in 1-2 independent experiments). Error bars represent SEM. (c,d) 
A TEAD1-bound CRM near SOX9 (Fig. 7e) was fused to a minimal promoter and GFP, and 
injected into zebrafish embryos. In (c), a SOX9 CRM drove strong GFP expression in the 
pancreatic domain of 48 hpf zebrafish embryos (dotted circle, left panel), which was 
disrupted by a mutation in the TEAD recognition sequence (right). A midbrain-specific 
enhancer was used as internal control of transgenesis. Note that this experiment assessed 
activity of a single SOX9 CRM, which does not necessarily fully recapitulate the expression 
of endogenous sox9b. In the graph, +, +/− and − represent strong, weak and absent GFP 
expression in the pancreatic domain, respectively (n=110-140 embryos per condition, Chi-
squared test P=1.37×10−83). (d) Immunofluorescence analysis of pancreatic MPCs in 
zebrafish embryos injected at one- to two-cell stage with constructs containing SOX9, 
MAP3K1 and FOXA2 CRMs driving GFP. Images show GFP in Pdx1+/Nkx6.1+ cells at 
24/48 hpf, as indicated. In total, 8/10 CRMs yielded activity in Pdx1+/Nkx6.1+ progenitors 
(see also Supplementary Fig. 5b). The pancreatic progenitor domain is revealed by co-
expression of Pdx1+ and Nkx6.1+ (dashed lines). Note that in zebrafish Nkx6.1 is specific to 
MPCs within embryonic pancreas47. g: Pdx1+ gut cells, s: somites showing crossreactivity 
with anti-Pdx1 serum. (e) Percentage of transgenic embryos with CRM-driven GFP 
expression in MPCs, or in negative controls (neg.) (quantifications shown in Supplementary 
Table 21).
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Figure 6. 
YAP is expressed in the nucleus of pancreatic MPCs, and shows co-occupancy with TEAD1 
at MPC enhancers. (a) YAP is detected in the nucleus of PDX1+ in vivo MPCs from human 
Carnegie Stage 18 pancreas. (b) In 10 weeks post-conception (WPC) human pancreas YAP 
expression is strong in nuclei of PDX1+ progenitors, but shows markedly diminished signal 
intensity in NGN3+ progenitors (white arrow). Image depicts 5 cells in human embryonic 
pancreas 10 WPC. (c) Yap is detected in the nucleus of Sox9+ MPCs from mouse E12.5 
embryonic pancreas (white arrow), whereas Yap is diffuse or absent in Ngn3+ endocrine 
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progenitor cells (hollow arrowheads). (d) YAP is excluded from the nucleus in hESCs-
derived pancreatic NGN3+ progenitor cells (hollow arrowheads). (e) ChIP-qPCR analysis of 
YAP occupancy in chromatin from in vitro MPCs shows that TEAD1-bound regions are 
often co-bound by YAP.
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Figure 7. 
TEAD and YAP regulation of pancreas development. (a) Human in vitro MPCs were 
incubated with VP 24 hours to disrupt TEAD-YAP interactions, causing downregulation of 
genes associated with TEAD1-bound enhancers. Data was normalized by PBGD. Bars show 
mean values from 2 independent experiments, and points represent mean of 2 technical 
replicates. (b-d) VP treatment of E11.5 mouse pancreatic explants downregulated orthologs 
of TEAD1-bound genes, inhibited proliferation and reduced growth of pancreatic epithelial 
cells. Explants were treated with VP for 24 hours, washed, and incubated 24 hours before 
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analysis. Data was normalized to Gapdh. *Two-tailed t test P<0.05 (individual values listed 
in Supplementary Table 22). Error bars represent SD from 3 independent experiments (each 
with n=2-4 embryos/condition). In (c) the percentage of proliferating epithelial cells was 
quantified with E-Cadherin and EdU immunolocalization. Two-tailed Mann-Whitney P 
value is shown for 3 experiments (each with n=2-3 pancreas/condition). In (d) GFP+ area in 
Sox9-EGFP transgenic embryo explants is shown at day 3 compared to day 1. Two-tailed 
Mann-Whitney test P values are shown for 3 experiments (each with n=2-4 buds/condition). 
In (c) and (d) boxes are IQR and median, whiskers 1.5 × IQR or extreme values. (e) 
Snapshot of the human SOX9 locus, encoding a regulator of MPC growth14. The CRM 
tested in functional assays in Figure 5c and Figure 7f is highlighted. (f) yap1 inhibition 
decreased pancreatic sox9b expression. Injection of Mo-yap1 caused a reduction or absence 
of sox9b mRNA in the pancreatic domain (arrow) in 50/102 48 hpf embryos. Control 
embryos showed pancreatic sox9b expression in 100/100 embryos (Chi-squared P 
2.61×10−15). Note that control and morphant embryos always showed sox9b expression in 
fin buds (fb). (g) Injection of Mo-yap1 (n=10 embryos) or the TEAD-EnR dominant 
negative (n=12 embryos) caused a decreased number of sox9b+/Pdx1+ pancreatic 
progenitors (dotted lines) in 24 hpf embryos vs. controls (n=9 embryos). Sox9b was detected 
by in situ hybridization and Pdx1 by immunofluorescence. The graph reflects the total 
number of pancreatic progenitors in each embryo. Mo-yap1 also increased ectopic 
expression of pancreatic markers (Supplementary Figure 7b). Student’s t test P values and 
SD are shown.
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Figure 8. 
YAP/TEAD-dependent activation provides a regulatory switch for pancreatic MPC 
enhancers. A significant number of pancreatic MPC enhancers is co-bound by known stage-
specific TFs along with TEAD and YAP. During pancreatic differentiation YAP is rapidly 
excluded from the nucleus and its expression is reduced, causing inactivation of MPC stage-
specific enhancers. This simplified model depicts inhibition of YAP through Hippo kinase-
induced phosphorylation or degradation, although additional non-mutually exclusive 
mechanisms for dynamic inhibition of YAP signaling are plausible. The model is supported 
by evidence showing that chemical or genetic inhibition of YAP and TEAD function causes 
inhibition of MPC enhancers.
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